|
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®
|
06 June 2019 |
|
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
|
03 June 2019 |
|
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
|
22 May 2019 |
|
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
|
14 May 2019 |
|
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians
|
07 May 2019 |
|
Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off
|
09 April 2019 |
|
Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre
|
03 April 2019 |
|
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
|
01 April 2019 |
|
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
|
27 March 2019 |
|
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
|
15 March 2019 |